744224
Last Update Posted: 2010-01-13
Recruiting has ended
Males accepted | 18 Years-35 Years |
8 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.
Eligibility
Relevant conditions:
Glucocorticoid-induced Glucometabolic Abnormalities
Glucocorticoid-induced Beta-cell Dysfunction
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov